Molecular Partners (NASDAQ:MOLN) Trading Down 0.5% – Time to Sell?

Molecular Partners AG (NASDAQ:MOLN)’s stock price traded down 0.5% on Tuesday . The company traded as low as $3.81 and last traded at $3.86. 13,897 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 19,646 shares. The stock had previously closed at $3.88.

Analysts Set New Price Targets

Separately, Lifesci Capital initiated coverage on shares of Molecular Partners in a report on Tuesday, March 11th. They issued an “outperform” rating and a $12.00 target price on the stock.

Molecular Partners Trading Up 2.8 %

The stock has a 50 day simple moving average of $4.68 and a 200-day simple moving average of $5.14. The firm has a market capitalization of $158.07 million, a P/E ratio of -1.82 and a beta of 1.06.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Thursday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. As a group, sell-side analysts expect that Molecular Partners AG will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL lifted its stake in Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,353,968 shares of the company’s stock after buying an additional 910,747 shares during the quarter. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 as of its most recent filing with the Securities & Exchange Commission. 26.55% of the stock is owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.